triple agonist glp 1 Media Centre

Evolving Role of Double and Triple Therapy With GLP-1 Receptor Agonists in Obesity and Cardiovascular Disease

21.25

★★★★☆4.8 (126)

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

20.39

★★★★★4.9 (98)

Retatrutide: A Triple Threat in Weight Loss Imagine a medication that targets three powerful hormones—GLP-1, GIP, and Glucagon receptors—to help you shed serious weight, curb cravings, and boost your metabolism. That's Retatrutide,

22.14

★★★★★5.0 (157)

Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)

29.66

★★★★★4.7 (84)

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms in: Journal of Endocrinology Volume 263 Issue 1 (2024)

22.09

★★★★★4.9 (203)

There's a new name in the GLP conversation — and it's worth paying attention to. Retatrutide is a triple-agonist therapy that targets GLP-1, GIP, and glucagon receptors simultaneously. In clinical trials, it

23.27

★★★★★5.0 (176)

Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair

26.81

★★★★★4.8 (132)